Kyrcz-Krzemień S - Search Results

1

Profile of serum biomarkers in eosinophilic disorders.

Helbig G, Francuz T, Hus M, Wiśniewska-Piąty K, Kyrcz-Krzemień S. Helbig G, et al. Eur J Intern Med. 2016 Apr;29:e19-20. doi: 10.1016/j.ejim.2016.01.008. Epub 2016 Jan 19. Eur J Intern Med. 2016. PMID: 26809865 No abstract available.

2

Frequency of abnormal T-cells in hypereosinophilic syndrome and hypereosinophilia of undetermined significance- Extended follow-up.

Helbig G, Dziaczkowska-Suszek J, Francuz T, Torba K, Kyrcz-Krzemień S. Helbig G, et al. Eur J Intern Med. 2016 Nov;35:e14-e15. doi: 10.1016/j.ejim.2016.05.024. Eur J Intern Med. 2016. PMID: 27267517 No abstract available.

3

Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome.

Helbig G, Hus M, Hałasz M, Dudziński M, Więcławek A, Stachowicz M, Soja A, Kyrcz-Krzemień S. Helbig G, et al. Med Oncol. 2012 Jun;29(2):1073-6. doi: 10.1007/s12032-011-9831-1. Epub 2011 Jan 22. Med Oncol. 2012. PMID: 21258876

4

Diagnostic and therapeutic management in patients with hypereosinophilic syndromes.

Helbig G, Kyrcz-Krzemień S. Helbig G, et al. Pol Arch Med Wewn. 2011 Jan-Feb;121(1-2):44-52. Pol Arch Med Wewn. 2011. PMID: 21346698 Free article. Review.

5

Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation.

Helbig G, Soja A, Bartkowska-Chrobok A, Kyrcz-Krzemień S. Helbig G, et al. Am J Hematol. 2012 Jun;87(6):643-5. doi: 10.1002/ajh.23193. Epub 2012 Mar 31. Am J Hematol. 2012. PMID: 22473587 Free article.

6

Diversity of clinical manifestations and response to corticosteroids for idiopathic hypereosinophilic syndrome: retrospective study in 33 patients.

Helbig G, Wiśniewska-Piąty K, Francuz T, Dziaczkowska-Suszek J, Kyrcz-Krzemień S. Helbig G, et al. Leuk Lymphoma. 2013 Apr;54(4):807-11. doi: 10.3109/10428194.2012.731602. Epub 2012 Oct 5. Leuk Lymphoma. 2013. PMID: 22988896

7

Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.

Helbig G, Kyrcz-Krzemień S. Helbig G, et al. Am J Hematol. 2014 Jan;89(1):115. doi: 10.1002/ajh.23588. Epub 2013 Oct 15. Am J Hematol. 2014. PMID: 24009127 Free article. No abstract available.

8

Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance.

Helbig G, Hus M, Francuz T, Dziaczkowska-Suszek J, Soja A, Kyrcz-Krzemień S. Helbig G, et al. Med Oncol. 2014 Jan;31(1):815. doi: 10.1007/s12032-013-0815-1. Epub 2013 Dec 14. Med Oncol. 2014. PMID: 24338273 Free PMC article.

9

Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.

Helbig G, Soja A, Świderska A, Hus M, Kyrcz-Krzemień S. Helbig G, et al. Leuk Lymphoma. 2016;57(3):708-10. doi: 10.3109/10428194.2015.1065983. Epub 2015 Oct 2. Leuk Lymphoma. 2016. PMID: 26430910 No abstract available.

10

The kinetics of mRNA transforming growth factor beta1 expression and its serum concentration in graft-versus-host disease after allogeneic hemopoietic stem cell transplantation for myeloid leukemias.

Kyrcz-Krzemień S, Helbig G, Zielińska P, Markiewicz M. Kyrcz-Krzemień S, et al. Med Sci Monit. 2011 Jun;17(6):CR322-8. doi: 10.12659/msm.881804. Med Sci Monit. 2011. PMID: 21629186 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

125 results

Search Page

Filters